BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alkermes plc (ALKS) Files Resale Shelf Registration in Connection with Elan Corporation PLC (ELN) Shareholder Agreement


2/17/2012 6:47:08 AM

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today filed a resale shelf Registration Statement on Form S-1 with the Securities and Exchange Commission (“SEC”) relating to the potential future sales by a subsidiary of Elan Corporation, plc (“Elan”) of up to 31,900,000 ordinary shares of Alkermes plc (“Alkermes”), pursuant to the shareholder’s agreement between Alkermes and Elan entered into in connection with the business combination of Elan’s drug technology unit and Alkermes, Inc., which was completed in September 2011. Any sale of these shares is governed by the terms of the shareholder’s agreement. Under the shareholder’s agreement, Elan will have the right to sell up to approximately 13 million shares of the registered amount in a marketed, underwritten public offering after the expiry of the initial lock-up period, unless Alkermes consents to the sale of a greater number of shares. The remaining shares will be saleable on a delayed basis. Any offering of these securities will be made only by means of a prospectus and a related prospectus supplement.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES